HCA Healthcare, Inc. - 10-Q Summary (Quarter Ended September 30, 2000)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for HCA -- The Healthcare Company (formerly Columbia/HCA Healthcare Corporation) for the period ended September 30, 2000. HCA is a holding company owning and operating 189 hospitals and 76 freestanding surgery centers across 24 U.S. states, England, and Switzerland. The company is currently undergoing a significant restructuring to focus on core communities, involving divestitures and spin-offs of non-core assets.
Key Financial Metrics
| Metric | Quarter 2000 | Quarter 1999 | 9 Months 2000 | 9 Months 1999 |
|---|---|---|---|---|
| Revenues | $4,093 million | $3,899 million | $12,497 million | $12,715 million |
| Net Income | $174 million | $138 million | $198 million | $566 million |
| Diluted EPS | $0.31 | $0.24 | $0.35 | $0.95 |
| Operating Cash Flow (9mo) | $1,114 million (2000) vs $806 million (1999) | |||
| Total Debt | Long-term: $5,426 million; Current portion: $1,434 million | |||
| Cash & Equivalents | $180 million (Sept 30, 2000) | |||
| Working Capital | Deficit of $353 million (due to settlement accrual) |
Material Changes vs. Prior Period
- Quarterly Performance: Net income increased 26.3% to $174 million, driven by a 5.0% revenue increase and improved operating margins. Same-facility revenue grew 6.9%.
- Year-to-Date Performance: Net income decreased 65.0% to $198 million. This decline is primarily due to a one-time $745 million pretax charge recorded in Q2 2000 for a settlement with the federal government. Excluding this charge, income before taxes would have increased 13.3%.
- Restructuring: The company recognized a $17 million impairment charge for assets held for sale in Q3 2000, compared to $160 million in the same period of 1999. Gains on sales of facilities were $20 million in Q3 2000 versus $0 in Q3 1999.
- Debt and Liquidity: Interest expense rose to $147 million in Q3 2000 from $122 million in 1999 due to higher interest rates and settlement-related interest. The company issued $750 million in notes in August 2000 and $500 million in September 2000 to reduce revolving credit facility balances.
Guidance, Outlook, Risks, and Unusual Items
- Government Settlement: A $745 million settlement with the DOJ regarding DRG coding, outpatient lab billing, and home health issues was accrued in Q2. The settlement is subject to final approval and the resolution of pending criminal investigations, with a deadline extended to December 31, 2000.
- Legal Risks: The company faces ongoing federal and state investigations, multiple qui tam (whistleblower) actions, and shareholder derivative suits. Management states that ultimate liabilities cannot be reasonably estimated but could have a material adverse effect.
- Operational Outlook: Management expects continued pressure from managed care payers and the Balanced Budget Act of 1997. The strategy focuses on increasing patient volume, controlling costs, and optimizing core assets through selective divestitures and acquisitions.
- Capital Allocation: The company has authorized $1 billion in stock repurchases (announced March 2000) and another $1 billion (announced Nov 1999). Approximately $495 million in forward purchase contracts remain outstanding.
Investor Verification Checklist
- Settlement Finality: Verify the status of the $745 million DOJ settlement and the resolution of the associated criminal investigations by the December 31, 2000 deadline.
- Legal Exposure: Monitor the outcome of pending qui tam actions and shareholder derivative suits, as these could result in substantial additional liabilities.
- Repayment of Debt: Confirm the company's ability to service its debt load, particularly given the working capital deficit caused by the settlement accrual.
- Operational Metrics: Track same-facility revenue growth and revenue per equivalent admission to assess the effectiveness of cost management and pricing strategies amidst payer mix shifts.
- Stock Repurchases: Review the settlement of forward purchase contracts and the execution of the authorized stock buyback programs.